NSE / BSEHealthcare
β‚Ή586.00+8.25+1.43%
P/E74.0Mkt Capβ‚Ή9.88 K CrEV/EBITDA36.5

Metropolis Healthcare Limited

P/E74.0Mkt Capβ‚Ή9.88 K CrEV/EBITDA36.5
Company Profile

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 19.39% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+8.5%); Jan the lowest (-8.9%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-2.8%Negative MonthJan 2026: -2.78%+1.5%Neutral MonthFeb 2026: +1.48%-8.8%Negative MonthMar 2026: -8.84%+9.9%Positive MonthApr 2026: +9.91%+8.8%Positive MonthMay 2026: +8.82%+4.1%Positive MonthJun 2026: +4.08%+8.5%*Positive MonthJul 2026: +8.53%β€”β€”β€”β€”β€”
2025-13.4%Negative MonthJan 2025: -13.41%-11.7%Negative MonthFeb 2025: -11.65%-1.5%Neutral MonthMar 2025: -1.52%+9.0%Positive MonthApr 2025: +8.96%-1.2%Neutral MonthMay 2025: -1.23%+1.6%Neutral MonthJun 2025: +1.61%+16.9%Positive MonthJul 2025: +16.90%+9.8%Positive MonthAug 2025: +9.75%-6.6%Negative MonthSep 2025: -6.60%-4.0%Negative MonthOct 2025: -4.01%-1.6%Neutral MonthNov 2025: -1.61%-0.2%Neutral MonthDec 2025: -0.25%
2024-2.6%Negative MonthJan 2024: -2.64%-1.9%Neutral MonthFeb 2024: -1.90%+7.8%Positive MonthMar 2024: +7.76%+5.2%Positive MonthApr 2024: +5.21%+4.9%Positive MonthMay 2024: +4.93%+3.7%Positive MonthJun 2024: +3.75%+7.0%Positive MonthJul 2024: +6.98%+1.1%Neutral MonthAug 2024: +1.15%+2.4%Positive MonthSep 2024: +2.38%-2.1%Negative MonthOct 2024: -2.09%-0.1%Neutral MonthNov 2024: -0.12%-3.2%Negative MonthDec 2024: -3.18%
2023+1.3%Neutral MonthJan 2023: +1.27%-2.5%Negative MonthFeb 2023: -2.54%-4.6%Negative MonthMar 2023: -4.65%+0.2%Neutral MonthApr 2023: +0.22%+4.2%Positive MonthMay 2023: +4.17%+14.6%Positive MonthJun 2023: +14.56%-8.2%Negative MonthJul 2023: -8.21%-2.2%Negative MonthAug 2023: -2.19%+8.8%Positive MonthSep 2023: +8.80%-3.6%Negative MonthOct 2023: -3.65%+21.1%Positive MonthNov 2023: +21.11%-1.5%Neutral MonthDec 2023: -1.48%
2022-26.9%Negative MonthJan 2022: -26.92%-22.3%Negative MonthFeb 2022: -22.34%+4.3%Positive MonthMar 2022: +4.33%+18.0%Positive MonthApr 2022: +17.98%-32.7%Negative MonthMay 2022: -32.73%-12.9%Negative MonthJun 2022: -12.93%+12.3%Positive MonthJul 2022: +12.28%-9.1%Negative MonthAug 2022: -9.15%+8.2%Positive MonthSep 2022: +8.17%+8.9%Positive MonthOct 2022: +8.87%-13.2%Negative MonthNov 2022: -13.24%-9.5%Negative MonthDec 2022: -9.54%
2021β€”β€”β€”β€”β€”+9.8%Positive MonthJun 2021: +9.84%+0.3%Neutral MonthJul 2021: +0.27%-0.9%Neutral MonthAug 2021: -0.85%-4.3%Negative MonthSep 2021: -4.27%+9.7%Positive MonthOct 2021: +9.71%+11.2%Positive MonthNov 2021: +11.15%+4.5%Positive MonthDec 2021: +4.46%
AvgΒ±SD-8.9%Β±10.2%-7.4%Β±8.6%-0.6%Β±6.0%+8.5%Β±5.9%-3.2%Β±15.1%+3.5%Β±8.5%+6.1%Β±8.2%-0.3%Β±6.1%+1.7%Β±6.3%+1.8%Β±6.2%+3.5%Β±11.7%-2.0%Β±4.5%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.215x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή1.22 K Crβ–² 10.3%
EBITDA Growthβ€”
Net Profitβ‚Ή125.00 Crβ–² 7.8%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 250.0%
Revenue CAGR 5Y10.6%
EBITDA CAGR 5Y8.7%
Net Profit CAGR 5Y0.7%
NP Growth 1Y7.8%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή1.22 K Crβ€”β‚Ή125.00 Crβ€”β€”10.0%10.3%7.8%
Mar 2024β‚Ή1.10 K Crβ€”β‚Ή116.00 Crβ€”β€”11.3%3.5%-16.5%
Mar 2023β‚Ή1.07 K Crβ€”β‚Ή139.00 Crβ€”β€”14.9%-7.9%-30.5%
Mar 2022β‚Ή1.16 K Crβ€”β‚Ή200.00 Crβ€”β€”23.8%41.8%1.0%
Mar 2021β‚Ή816.00 Crβ€”β‚Ή198.00 Crβ€”β€”27.9%22.7%76.8%
Mar 2020β‚Ή665.00 Crβ€”β‚Ή112.00 Crβ€”β€”21.9%14.5%10.9%
Mar 2019β‚Ή581.00 Crβ€”β‚Ή101.00 Crβ€”β€”24.3%19.8%5.2%
Mar 2018β‚Ή485.00 Crβ€”β‚Ή96.00 Crβ€”β€”26.4%19.8%9.1%
Mar 2017β‚Ή405.00 Crβ€”β‚Ή88.00 Crβ€”β€”32.8%16.0%15.8%
Mar 2016β‚Ή349.00 Crβ€”β‚Ή76.00 Crβ€”β€”31.3%37.4%76.7%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales2232543494054855816658161,1571,0661,1031,2171,288
Total Expenses1591832632893484344895748337928409441,002
EBIT / Operating Profit647186115137148176242324274263273286
OPM %29%28%25%29%28%25%26%30%28%26%24%22%22%
Other Income156393015205493221121716
Finance Costs2212331092531272317
Depreciation & Amortisation810121214153136608591105110
Profit Before Tax6965112131135149140246272179157162175
Tax %33%33%32%33%29%32%20%20%27%22%26%23%-
Net Profit / PAT4643768896101112198200139116125133
EPS (β‚Ή)47.1243.6479.5992.21100.3420.2222.1338.6538.9927.1322.6224.0925.81
Dividend Payout %3%0%101%57%0%66%36%21%21%29%18%0%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Metropolis Healthcare Limitedthis co.β‚Ή9.88 K Crβ‚Ή1.22 K Cr74.007.4536.4510.3%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Metropolis Healthcare Limited and the metrics that matter.

Browse the full Equiscale Academy